NCT04122313 Post-contracture Release Radiation for Dupuytren's Disease
| NCT ID | NCT04122313 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Minnesota |
| Condition | Dupuytren's Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2019-05-31 |
| Primary Completion | 2029-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2019-05-31 with a primary completion date of 2029-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine if the clinical impression of clinicians, ie that patients are improving with the current treatment pathway for Dupuytren's (contracture release followed by radiation), can be substantiated with scientific evidence.
Eligibility Criteria
Inclusion Criteria: * Diagnoses of Dupuytren's disease * English-speaking Exclusion Criteria: \- Patients with Dupuytren's disease who are not currently seeking treatment
Contact & Investigator
Leslie Chang
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT04122313 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dupuytren's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04122313 currently recruiting?
Yes, NCT04122313 is actively recruiting participants. Contact the research team at dupuytrensumn@umn.edu for enrollment information.
Where is the NCT04122313 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT04122313 clinical trial?
NCT04122313 is sponsored by University of Minnesota. The principal investigator is Leslie Chang at University of Minnesota. The trial plans to enroll 50 participants.